Yasuto Takeuchi

8PUBLICATIONS

54CO-AUTHORS

Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)Molecular targets

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (8)

Sort by Publication Date:

|May 12, 2026

Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 2026.

|Nov 28, 2025

Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B.

Ryu Sasaki, Shigeo Shimose, Issei Saeki

|Aug 28, 2025

Prognostic Impact of Gastrointestinal Immune-Related Adverse Events Depends on Nutritional Status in Cancer Patients Treated with Immune Checkpoint Inhibitors.

Shoichiro Hirata, Yoshiyasu Kono, Emi Tanaka

|Aug 21, 2025

Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.

Takeshi Hatanaka, Shigeo Shimose, Takanori Ito

|May 08, 2024

Response to the letter: "Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab".

Tatsuya Kikuchi, Yasuto Takeuchi, Kazuhiro Nouso

|Mar 15, 2024

Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.

Tatsuya Kikuchi, Yasuto Takeuchi, Kazuhiro Nouso

Pageof 2

Frequent Collaborators

Kazuhiro Nouso

Kazuya Kariyama

Motoyuki Otsuka

Takumi Kawaguchi

Tatsuya Kikuchi

Toshifumi Tada

Takeshi Hatanaka

Shigeo Shimose

Ryu Sasaki

Hideki Iwamoto

Frequent Collaborators

Kazuhiro Nouso

Kazuya Kariyama

Motoyuki Otsuka

Takumi Kawaguchi